Oncolytics Biotech Inc.
News from Oncolytics Biotech Inc. highlights the most recent developments
Published in Lab Law Weekly, September 7th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Oncolytics Biotech Inc..
Report 1: Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced positive results from its U.S. Phase I clinical trial examining the systemic administration of REOLYSIN(R) in patients with advanced cancers. The results indicate that REOLYSIN(R) can be delivered systemically to patients with advanced and metastatic cancers and cause anti-tumour activity.
"REOLYSIN(R) administered as a one-hour infusion on a monthly...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
Source: Lab Law Weekly (2007-09-07)
More Articles from Lab Law Weekly
- Allergies
Video: Food Allergies Mean Back-to-School Jitters for Millions of Students and Their Parents - American Legacy Foundation(R)
American Legacy Foundation Welcomes New Board Member - American Society for Quality
American Society for Quality Submits Written Statement on Food Safety to Congressional Subcommittee - Automotive Industry Action Group
AIAG Guideline Aims to Slash up to 30 Percent in Administrative Health Care Costs - Bausch & Lomb
Bausch & Lomb and Alcon Settle Advertising Lawsuit - Bionics
Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses - More from this issue of Lab Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
